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A B S T R A C T   
Objectives: To estimate treatment- and productivity-related costs associated with COPD in two different samples, 
and to analyse the association between the costs and moderate and severe exacerbations. 
Methods: We performed a baseline visit and four telephone-interviews during a one-year follow-up of 81 COPD 
cases and 132 controls recruited from a population-based sample, and of 205 hospital-recruited COPD patients. 
COPD was defined by post-bronchodilator spirometry. Total costs consisted of treatment related costs and costs 
of productivity losses. Exacerbation-related costs were estimated by multivariate median regression. 
Results: The average annual disease-related costs for a COPD patient from the hospital sample was nearly twice as 
high as for a COPD case from the population sample (€26,518 vs €15,021), and nearly four times as high as for a 
control subject (€6740). For both sampling sources, the average annual costs of productivity losses were sub-
stantially higher than the treatment related costs (€17,014 vs €9,504, €11,192 vs €3,829, and €4494 vs €2,246, 
for the hospital COPD patients, the population-based COPD cases, and the controls, respectively). Severe exac-
erbations were an important cost driver for the treatment related costs in both COPD groups. Moderate exac-
erbations explained all the costs of productivity losses in the population-based COPD cases, but did not affect the 
costs of productivity losses in the hospital-recruited COPD patients. 
Conclusion: We found that there were significant incremental costs associated with COPD, and the treatment 
related costs were significantly affected by exacerbations. The costs of productivity losses substantially exceeded 
the treatment related costs in both sampling sources.   
1. Introduction 
Chronic obstructive pulmonary disease (COPD) has become the third 
leading cause of death [1]. Many COPD patients experience acute ex-
acerbations (AECOPD), often with infectious cause. Acute exacerbations 
of COPD are associated with increased mortality, increased lung func-
tion decline, and an increased use of healthcare resources [2–8]. 
The actual costs of AECOPD in general populations are difficult to 
obtain from the existing literature. This is partly due to differences in 
healthcare organization and different levels of costs across regions and 
countries, but methodological approaches also vary immensely. Most 
previous studies have been performed in selected populations [9,10], 
use self-reported or registry-based diagnosis rather than diagnosis based 
on post-bronchodilator spirometry [9,11], or leave out important costs 
like those induced by lower productivity [12–18]. In addition, costs may 
be estimated from a top-down [9], or a bottom-up [11] approach, they 
may be estimated by attributing costs or by adapting an incremental 
(also often called the excessive or marginal) cost approach, and costs can 
be registered prospectively or collected in retrospect. For a chronic, 
long-lasting disease such as COPD, with associated comorbidities, we 
would advocate that a prospective, population-based, bottom-up study 
that presents incremental treatment related costs and costs of produc-
tivity losses would provide decision makers with the most reliable and 
relevant cost estimates. 
To our knowledge, the only such prospective, population-based 
bottom-up study so far is the OLIN (Obstructive Lung disease in North-
ern Sweden) study. However, they evaluated only the treatment related 
costs of exacerbations [12,19], and did not use an incremental cost 
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approach. 
The EconCOPD-study was a prospective, one-year study of health-
care utilisation including COPD patients from both a population-based 
sample and a hospital population, as well as in population-based con-
trol subjects without COPD. We have previously shown that the hospital- 
recruited COPD patients had threefold incremental treatment-related 
costs compared to the population-based COPD cases [20]. 
The main aim of the current analysis was to estimate the societal, 
treatment-related costs and costs related to productivity losses associ-
ated with COPD in a population-based sample compared to a hospital- 
recruited sample, and to analyse the association between costs and 
moderate and severe exacerbations. A secondary aim not studied pre-
viously, was to shed light on the effects of studying exacerbations in 
selected populations by comparing our population-based estimates to 
the costs in the hospital-recruited sample. 
The current analysis thus adds costs of productivity losses to our 
previous work [20], and furthermore, it estimates the fraction of costs 
attributable to moderate and severe exacerbations. 
2. Methods 
The EconCOPD-study took place between March 2005 and August 
2006 at Haukeland University Hospital, in Bergen, Norway. The 
Regional Committee for Medical and Health Research Ethics in Western 
Norway approved the study (REK Vest case number 252.04), and all 
participants provided written consent. 
2.1. Study population and design 
Details on sampling procedures and data collection have been pub-
lished previously [21]. Briefly, the participants included in the 
EconCOPD-study were grouped in three subsamples based on sample 
source and COPD-status, i.e. controls without COPD and COPD cases from 
a follow-up of the population-based Hordaland Country Respiratory 
Health Survey [22], and thirdly COPD patients from Haukeland Uni-
versity Hospitals’ patient register. The controls enabled us to estimate 
incremental costs of COPD, i.e. the excessive costs of an index disease by 
comparing to a group without the index disease, and, additionally, to 
adjust for the baseline risk of having exacerbation-like symptoms [23]. 
All participants were current or former smokers of �2.5 pack years, 
and at least 40 years old at time of inclusion. All participants were 
examined with post-bronchodilator spirometry abiding to ATS standards 
[24]. COPD was defined as a ratio of the forced expiratory volume in 1 s 
(FEV1) to the forced vital capacity (FVC) < 0.70 and FEV1 < 80% of 
predicted [25]. The control subjects had an FEV1/FVC-ratio > 0.70 and 
FEV1 > 80% of predicted. 
During the baseline visit, participants were interviewed about their 
smoking habits, education, employment status, comorbidities, and 
medication use. Later, participants were interviewed by telephone after 
12, 24, 36, and 52 weeks regarding respiratory symptoms, absence from 
work, medication use, and healthcare utilisation. A moderate exacer-
bation was defined as the use of antibiotics or corticosteroids due to 
respiratory symptoms, and a severe exacerbation as hospitalisation due 
to respiratory disease. Number of comorbid conditions were defined as 
the count of positive answers to a slightly modified Charlson Comor-
bidity Index [26]. The online supplement includes translations of the 
relevant interviewer questionnaires. 
2.2. Costs 
The total costs incurred by each participant was the sum of the 
treatment-related costs and costs of productivity losses from the 
perspective of the society. All treatment-related costs were estimated by 
multiplying rates of utilisation with relevant unit costs. The components 
of treatment-related costs were medication use, GP consultations, 
specialist consultations, emergency care, hospitalisations, 
physiotherapy, nursing services, home healthcare providers, home ox-
ygen treatment, and rehabilitation. All unit costs are given in e-Table 1a 
and e-Table 1b, and details on how unit costs were estimated are given in 
the online supplement as well as in a previous publication [20]. The 
productivity losses were estimated by asking participants in detail 
concerning their absence from paid work [27], and divided in short-term 
and long-term disease-related absence. The cost of this productivity loss 
was estimated with a human capital approach, by multiplying the total 
number of lost days by the mean income per day according to sex, age, 
and education for 2006 given by SSB (Statistics Norway), and adding 
20% to include all costs for employers [28]. Hence, as a proxy for the 
cost of lost productivity we have used the total employers’ compensation 
per worker [29]. In Norway, the employers’ costs approximate 20%, or 
even a bit more, making our estimates somewhat conservative [30]. All 
costs were transformed from 2006-NOK to Euros (€) using the mean 
exchange rate for year 2006 (8.05 NOK ¼ 1 €). 
2.3. Statistical analyses 
To test the distribution of characteristics across participant groups 
we used parametric (t-test, ANOVA) or non-parametric (Chi2, Kruskal- 
Wallis) tests. P-values < 0.05 were considered statistically significant. 
Due to skewed distribution of the cost components, we chose Kruskal- 
Wallis tests with ties for the initial unadjusted analyses comparing 
costs across the three groups. 
We performed multivariate regression analyses estimating costs 
attributed to exacerbations and other covariates. We chose quantile 
median regression [31] which is a non-parametric method providing 
coefficients in the same unit of measurement as the outcome variable. 
For the main multivariate analyses, we fitted two separate multiple 
median regression models; one comparing cases to controls, and one 
comparing patients to controls. We analysed the treatment related costs 
and the costs related to production losses separately for both of these 
comparisons. The regression analyses were performed two times in each 
comparison with differing adjustment variables in the two sub-models. 
The “basic” model adjusted for severity of COPD according to 
GOLD-stages II-IV (GOLD-stage II defined by FEV1 50–80% of predicted, 
GOLD-stage III by FEV1 30–50% of predicted, and GOLD-stage IV by 
FEV1 < 30% of predicted), gender, age, comorbidity score, educational 
level, and pack years smoked. The “exacerbations” model adjusted for 
the basic variables and additionally for both moderate and severe ex-
acerbations. In the comparison of cases to controls, we combined GOLD 
stage 3 and 4 due to few cases with severe airflow limitation. 
All analyses were performed using Stata SE 15.1 (StataCorp, College 
Station, TX, USA). 
3. Results 
3.1. Characteristics 
In total, 418 out of 471 included participants completed one year of 
follow-up, of which 132 were controls (97% completed follow-up), 81 
COPD cases (90% completed follow-up), and 205 COPD patients (84% 
completed follow-up). Characteristics at baseline for each of the three 
study groups, including exacerbation rates during follow-up, are sum-
marised in Table 1. Exclusion of participants above retirement age did 
not change the pattern of differences between the sampling sources (e- 
Table 2). 
E-table 3 shows the annual utilisation of healthcare services and the 
annual productivity loss, which was multiplied by the unit costs to 
provide the unadjusted annual costs of healthcare utilisation and pro-
ductivity loss (Table 2). The group of COPD patients incurred signifi-
cantly higher costs than the other two groups. The total mean costs per 
person were € 26,518, €15,021, and € 6740 for the patients, cases, and 
controls respectively (p < 0.001). In the online supplement, we show the 
same analyses when retirees are excluded (e-tables 4 and 5). 
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3.2. Incremental cost models 
After estimating costs related to disease treatment and lost produc-
tivity, we wanted to evaluate the incremental or excessive costs of 
COPD. In regression models of costs including both subjects with and 
without COPD, the incremental costs of COPD are given by the co-
efficients for a categorical variable where control subjects constitute the 
reference category. 
We first modelled the treatment-related costs, comparing cases and 
controls (Fig. 1a). Moderate and severe exacerbations were evaluated in 
separate models, and were added to a basic model, to be able to visualize 
how much of the incremental costs that were explained by 
Table 1 
Characteristics of hospital- and population-recruited COPD cases and 
















Male, N (%) 123 (60%) 53 (65%) 69 (52%)  




68 (33%) 38 (47%) 63 (48%) * 
Former smoker, N 
(%) 
137 (67%) 43 (53%) 69 (52%)  
Pack years, mean 
(SD) 
32.7 (31.0) 32.3 (35.6) 15.6 (12.3) ** 
Educational level 
Primary, N (%) 
75 (37%) 32 (40%) 27 (20%) ** 
Secondary, N (%) 100 (49%) 30 (37%) 63 (48%)  
University, N (%) 30 (15%) 19 (23%) 42 (32%)  
FEV1% predicted 
�80%, N (%)   
132 (100%) ** 
�50%, <80%, N 
(%) 
103 (50%) 69 (85%)   
�30%, <50%, N 
(%) 
68 (33%) 8 (10%)   









0.7 (1.0) 0.4 (0.9) 0.1 (0.4) ** 
Severe, mean (SD) 0.3 (0.6) 0.0 (0.1) 0.0 (0.1) ** 
Total number of 
exacerbations 
in group 
203 31 15  
Maintenance 
therapy, N (%) 




146 (71%) 28 (35%) 15 (11%) ** 
Pneumococcus 97 (47%) 4 (5%) 2 (2%) ** 
Oxygen therapy, 
N (%) 
19 (9%) 0 0 ** 
Employment 
status at 
baseline, N (%) 
Paid job 
36 (17) 31 (38) 94 (71) ** 
Retired 94 (46) 29 (36) 26 (20)  
Disability pension 71 (35) 17 (21) 10 (8)  
Other*** 4 (2) 4 (5) 2 (1)  
COPD ¼ chronic obstructive pulmonary disease. SD ¼ standard deviation. FEV1 
¼ forced expiratory volume in 1 s. Iqr ¼ interquartile range. BMI ¼ body mass 
index. 
Categorical variables tested by Chi2 test, and continuous variables by test for 
trend across ordered groups where controls ¼ rank 1, cases ¼ rank 2, and pa-
tients ¼ rank 3. * ¼ p < 0.05. ** ¼ p < 0.01. *** Students, unemployed, 
homemakers. 
Table 2 
Annual unadjusted costs per person by components of treatment related costs 
and costs related to productivity losses, according to participant status. All es-


















1812, 0 (0) 1304, 0 (0) p <
0.001 
Medication costs, 























mean, median (iqr) 
564, 0 (489) 202, 0 (0) 2, 0 (0) p <
0.001 
Oxygen treatment, 
mean, median (iqr) 
221, 0 (0) 0, 0 (0) 0, 0 (0) p < 
0.001 
Total treatment 
























7777, 0 (0) 2094, 0 (0) p < 
0.001 
Total costs of 
productivity lossesb, 









Total costs (treatment- 
related þ costs of 
productivity losses), 










Fig. 1a. Cases and controls, multivariate median regression for treatment- 
related costs. “Basic” model adjusting for GOLD-stage, gender, age, per co-
morbid condition added, education, and packyears. “Exacerbations” model 
adjusting for all as in basic model þ both moderate and severe exacerbations. 
(For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
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exacerbations. In the basic model, COPD cases with FEV1 50–80% 
(GOLD stage 2) had annual treatment related costs of €490 (95% con-
fidence interval €132–849), whereas the corresponding number for 
cases with FEV1 less than 50% of predicted were €1938 (1266–2610). 
When we adjusted for moderate and severe exacerbations these numbers 
fell to €462 and €1,684, respectively – thus exacerbations explained 6% 
of treatment-related costs in GOLD stage 2 and 13% of treatment related 
costs in GOLD stage 3 and 4. Among the adjustment variables both 
comorbidities and sex were significant drivers of costs in all models. 
Next, we looked into costs incurred by productivity losses in cases 
and controls (Fig. 1b), and found that there were no significant costs of 
productivity losses in GOLD stage 2, whereas the annual costs of pro-
ductivity losses in GOLD stage 3 and 4 were €46,215 (30,190–62,240). 
When we adjusted for exacerbations, this cost was reduced and lost 
significance, showing that moderate exacerbations explained all costs 
related to productivity losses. 
When patients and controls were compared, treatment related costs 
in the basic models rose to €2252 (947–3557), €3221 (1773–4669) and 
€5684 (3955–7412) in GOLD stage 2, 3 and 4, respectively (Fig. 1c). 
When we added moderate and severe exacerbations to the model, costs 
were reduced by 27%, 40% and 48%, respectively. In the basic model 
with productivity losses the costs were €28,845 (19,383–38,307), 
€29,570 (18,759–40,382) and €48,338 (36,548–60,128) in GOLD stage 
2, 3 and 4, respectively (Fig. 1d). The addition of exacerbations did not 
add significantly to these models. All regression models are shown in the 
online supplement, e-Tables 6 and 7. 
* Kruskal-Wallis with ties. ** ANOVA. Test for trend; non-parametric 
trend test for hospital patients > population-based cases > control 
subjects. NA – not applicable. Iqr - interquartile range. a Healthcare 
professionals includes: general practitioners, specialist physicians in 
private practice, hospital physicians at outpatient clinics, emergency 
room visits, physiotherapists, home nursing services and house maid 
from the local healthcare authorities. b Includes a 20% increase to cover 
for employers’ costs. 
4. Discussion 
In a general population, we found that acute exacerbations of COPD 
explained 6% of annual treatment-related costs in GOLD stage 2 COPD, 
and 13% in the combined stage 3–4 COPD. For costs related to pro-
ductivity losses, there were no predictors associated with significantly 
higher costs for patients with FEV1 over 50% of predicted, whereas 
moderate exacerbations actually explained all costs associated with 
COPD in subjects with FEV1 less than 50% of predicted. 
Fig. 1b. Cases and controls, multivariate median regression for productivity 
losses. “Basic” model adjusting for GOLD-stage, gender, age, per comorbid 
condition added, education, and packyears. “Exacerbations” model adjusting 
for all as in basic model þ both moderate and severe exacerbations. (For 
interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
Fig. 1c. Patients and controls, multivariate median regression for treatment- 
related costs. “Basic” model adjusting for GOLD-stage, gender, age, per co-
morbid condition added, education, and packyears. “Exacerbations” model 
adjusting for all as in basic model þ both moderate and severe exacerbations. 
(For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
Fig. 1d. Patients and controls, multivariate median regression for productivity 
losses. “Basic” model adjusting for GOLD-stage, gender, age, per comorbid 
condition added, education, and packyears. “Exacerbations” model adjusting 
for all as in basic model þ both moderate and severe exacerbations. (For 
interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
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The average annual disease-related costs for a COPD patient 
recruited from a hospital register was nearly twice as high as for a COPD 
case recruited from the general population (€26,518 vs €15,021), and 
nearly four times as high as for a control subject (€6740). Moderate 
exacerbations had no impact on costs related to productivity losses in 
hospital-recruited COPD patients, where increasing severity of airflow 
obstruction was the only significant cost driver. Sampling source is of 
great importance when evaluating cost-of-illness studies, and one should 
use estimates from both general populations and hospital populations to 
retrieve information relevant for both decision makers and for more 
severely ill patients. 
It is challenging to compare our results to previous studies as 
different methods have been used. None of the previous studies evalu-
ating costs of COPD have estimated the incremental costs of exacerba-
tions or other explanatory variables in multivariate regression analyses, 
making our study a small but important contribution to a comprehensive 
understanding of the topic. The cost-of-illness study performed by 
Jansson et al. in the OLIN-study [32] adjusted for several explanatory 
variables to evaluate the relationship between costs and lung function, 
but did not adjust for exacerbations. Further analyses on the same ma-
terial from the OLIN-study was performed by Andersson et al. [12], and 
found that the average treatment related costs per moderate exacerba-
tion was SEK211, and per severe exacerbation SEK21,852. Additionally, 
they found that exacerbations were responsible for 35–45% of the total 
per capita treatment related costs, whereas in our study moderate ex-
acerbations were responsible for approximately 7% of the treatment 
related costs associated with both GOLD-stage 2 and with GOLD-stage 
3/4. Further on, in our study, severe exacerbations were responsible 
for very little (2%) of the treatment related costs associated with 
GOLD-stage 2, but also responsible for as much as 18% of the treatment 
related costs associated with GOLD-stage 3/4. This latter publication 
from the OLIN-study did not consider the costs of subjects without 
COPD, and hence, was not able to incorporate costs that were more 
difficult to attribute to a specific disease, and are therefore difficult to 
compare to our results. 
A study by Abudagga et al. [9] did not distinguish between treatment 
related and costs of productivity losses, but evaluated per-patient ex-
acerbations costs and looked upon predictors of exacerbations in a 
generalized linear model. They found that moderate exacerbations were 
responsible for a cost of $124 per patient per year, and severe exacer-
bations for $6260 per patient per year. Though not directly comparable 
to our method of estimating incremental costs, the relationship between 
the costs of the two types of exacerbations was the same -the severe 
exacerbations were 50 times more expensive than the moderate, both in 
Abudaggas’ study and for the attributable costs of exacerbations on 
treatment related costs for the cases in our study. 
We found that there were significantly increased treatment related 
costs associated with being female in the population-based sample of 
COPD cases, and this association was not altered when adjusting for 
moderate and/or severe exacerbations. This was not the case for the 
hospital-recruited COPD-patients. The explanation behind this is not 
certain, but several previous studies have seen the same pattern of 
increased health care utilisation and costs amongst women [33–35]. 
Postulated possible reasons for this have been that in post-menopausal 
women the quality of care is sub-optimal, and hence drives the costs 
[33]. More specifically for COPD, there has been seen a gender dimor-
phism [36], which could render the females more symptomatic at equal 
or even lower levels of smoking exposure. This is also supported by 
Watson et al. who found women to report a more severe dyspnoea score 
than men [37]. Some early studies also highlight this, stating that 
women are more likely to detect dyspnoea due to more attention to, and 
a higher awareness of, somatic sensations [38]. Kilic et al. found that 
women had more moderate exacerbations, and when experiencing se-
vere exacerbations, the time from onset of symptoms till admission was 
longer than for men, and their hospitalisation length was increased [39], 
all of which can contribute to more costly exacerbations for women. 
When the costs of severe exacerbations outnumber those of moderate 
exacerbations by a factor of 50, prevention of severity transition can 
save considerable costs in addition to having positive effects on the 
patients’ health. Several points where intervention can prevent an 
exacerbation going from moderate to severe have been studied [40]. 
Preventing further decline in lung function, vaccination, early detection 
of infections, and pulmonary rehabilitation are all important factors 
when trying to avoid severe exacerbations [41–46]. 
Although there has been debate around the usefulness of cost-of- 
illness studies [47], they provide help to decision-makers by giving an 
order of monetary magnitude for each disease studied [48]. If complying 
with recommendations for methods and interpretation, such as keeping 
to the bottom-up approach, cost-of-illness studies can be reliable and 
comparable, and hence a helpful tool in health economic decisions [28]. 
The main strength of our study, is that it included both general 
population-recruited COPD cases and controls, and COPD patients from 
a hospital register, making us able to clearly point out the excessive or 
incremental costs of COPD, as well as demonstrating the importance of 
study population. We have performed a comprehensive collection of cost 
items, and to our knowledge, no similar studies to date investigate both 
treatment related costs and costs of productivity losses in COPD. Addi-
tionally, our study was performed prospectively in a bottom-up manner, 
and recall bias was minimized due to telephone interviews being done 
every three months. The overall response rate was high (79%), and 
hence, we would argue that our results are applicable at the population 
level. 
Certain limitations need to be mentioned. First, the number of 
population-recruited cases was low, and few of these cases experienced 
severe exacerbations. Hence, the attributable costs of severe exacerba-
tions in the regression analyses for the cases are difficult to interpret. 
Yet, even in this group, there was significantly increased exacerbation 
risk with increasing severity of COPD, suggesting sufficient power [49]. 
Second, the participants in our study were recruited from Bergen and 11 
surrounding municipalities in Western Norway, and not from Norway in 
general. Nonetheless, a comparison between national Norwegian survey 
data for individuals in the same age range and the original cohort from 
which our participants were recruited from, showed no discrepancies 
[50]. Third, some would argue that the friction cost method (FCM) is 
favourable to the human capital approach (HCA) that we used, and that 
the HCA overstates the costs related to productivity loss. In the FCM, 
productivity loss is discounted based on the assumption that co-workers 
or unemployed persons cover swiftly for absenteeism [51]. However, in 
an attempt to capture alternative costs, there will nevertheless be a loss 
of productivity to the society when an individual is incapacitated. 
Additionally, the FCM might not suit the low Norwegian unemployment 
rates [52], making the supply of labour less flexible than elsewhere 
where unemployment rates are higher. Further, the FCM requires data 
that we did not possess, and hence, we cannot state for sure in which 
direction our results would have been altered if changing method to the 
FCM compared to the chosen HCA. Though, in general, it is accepted 
that the FCM generates lower total costs [28,29]. When we estimated 
costs due to lost productivity, one might argue that sick leave and 
disability pension represents transfers and not actual costs. This is a 
matter of cost perspective. The monetary value of sick leave payments 
and disability pensions are not actual costs, but the non-productivity 
caused by the disease (in this case COPD) is a cost. Measuring 
non-productivity by counting the days in sick leave and disability 
pension is in our opinion a valid approach that has been used by other 
authors [53]. Finally, we have neither included GOLD stage I partici-
pants nor never smokers. Most likely, this has given a higher cost 
average than if they had been included, but our clinical experience is 
that individuals in this group have few respiratory symptoms, and there 
is considerable overlap with asthma. Furthermore, the fixed criterion 
that we used for detecting chronic airway obstruction tends to over-
estimate disease prevalence compared to the alterative lower-limit of 
normal, and excluding individuals with FEV1 >80% brings the estimates 
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from these to criterions, closer [54]. 
Adding moderate exacerbations to our multiple-stage regression cost 
models changed the treatment related costs associated with COPD in the 
general population with about 7%. Adding severe exacerbations 
changed the treatment related costs associated with severe COPD in the 
general population with about 18%, implying that the costs in this group 
are partially explained by the occurrence of severe exacerbations. This 
result was expected since severe exacerbations were defined as hospi-
talisation due to respiratory disease, and hospitalisations were one of the 
components used to calculate the treatment related costs. 
More severe disease was associated with increased costs of produc-
tivity losses. The significance of this disappeared when taking moderate 
exacerbations into consideration, indicating that moderate exacerba-
tions are the main cost driver for costs related to productivity loss in 
COPD in the society. The population-based COPD cases were relatively 
young, there were few cases with severe airflow obstruction and the 
workforce participation rate was high. Thus, a priori one would expect a 
low occurrence and low impact of severe exacerbations on productivity 
losses. For the COPD patients, moderate exacerbations made no impact 
on the treatment related costs of COPD. Although exacerbations are 
frequent in this group [49], the level of treatment is probably so high 
that the “minor events” that moderate exacerbations represent do not 
lead to significantly increased treatment costs. On the other hand, 
approximately a third of the treatment related costs associated with 
severe COPD were explained by severe exacerbations. The cost of pro-
ductivity losses for the patients were not much affected by exacerbations 
which is reasonable when taking into account that 65% of the possible 
total working force in this group were receiving a disability pension, and 
hence not “available” for rendering any extra productivity loss. 
The annual costs of productivity losses dominated the total costs, and 
amounted to 2 to 3 times that of the treatment related costs, depending 
on which sampling source we used. For the costs of productivity losses, 
the exacerbations had less impact than what we saw for the treatment 
related costs which were more affected by exacerbations. Prevention of 
exacerbations is not only essential for the prognosis and wellbeing of the 
patients, but should also be a key target to reduce the treatment related 
costs associated with COPD. On the other hand, to reduce the costs of 
productivity losses in COPD, prevention of exacerbations would most 
likely have a modest effect in the costly individuals handled by the 
hospital clinics. Our study implicates that the costs of productivity losses 
need to be prevented at an early stage, before the COPD patients become 
disable or sick to a degree that affects their ability to work. To achieve 
this, we think it is essential to improve the diagnosis of COPD, reduce 
tobacco smoking even further, and make use of rehabilitation pro-
grammes more frequently and at earlier disease stages. 
In conclusion, we have found that there are significant incremental 
costs associated with having COPD, and that the treatment related costs 
are substantially affected by exacerbations. The costs of productivity 
losses significantly exceed the treatment related costs. To reduce the 
total costs of COPD, it is important both to avoid exacerbations, and to 
halter the development of more severe disease to sustain the working 
capacity of the patients as long as possible. 
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